Paradigm Biocapital Advisors LP
NEW YORK, NY · CIK 1855655 · 13F filing filed 2022-05-16
SEC-registered investment adviser since 2021 · limited partnership
- Assets managed$4.5bn
- Staff11 · 6 in investment roles
- Main clients (by assets)Private funds 90%
- Private funds2 (2 hedge) · $4.1bn gross assets
- Form ADV · 2026-08-27SEC adviser record
- Legal entityPARADIGM BIOCAPITAL ADVISORS LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$378.2m
reported value
+8.0% vs Q4 2021
25positions
65.2%in top 10
7 new
16 added
2 reduced
6 sold out
vs Q4 2021
Holdings, Q1 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ASCENDIS PHARMA A/S SPONSORED ADR | $37.7m9.98% | Added +103.5k |
| GLOBAL BLOOD THERAPEUTICS IN GBT | $33.5m8.86% | Added +186.3k |
| ARVINAS INC ARVN | $33.1m8.74% | Added +222.8k |
| LEGEND BIOTECH CORP LEGN | $30.2m7.99% | Added +445.8k |
| SIERRA ONCOLOGY INC COM NEW | $24.7m6.54% | Added +296.4k |
| VIRIDIAN THERAPEUTICS INC VRDN | $23.2m6.14% | Added +47.0k |
| INCYTE CORP INCY | $18.6m4.92% | New |
| IVERIC BIO INC OPHT | $15.3m4.05% | Added +94.8k |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $15.1m4.00% | Added +63.4k |
| IMMUNOCORE HLDGS PLC IMCR | $14.9m3.95% | Added +364.9k |
| HORIZON THERAPEUTICS PUB L HZNP | $14.3m3.79% | New |
| UNITED THERAPEUTICS CORP DEL UTHR | $13.6m3.59% | New |
| ZENTALIS PHARMACEUTICALS INC ZNTL | $13.3m3.51% | Reduced -12.9k |
| SYNDAX PHARMACEUTICALS INC SNDX | $12.2m3.22% | Added +248.3k |
| C4 THERAPEUTICS INC CCCC | $12.1m3.20% | Added +240.8k |
| OYSTER PT PHARMA INC OYST | $11.5m3.04% | Added +683.5k |
| PROTHENA CORP PLC PRTA | $9.8m2.59% | New |
| KYMERA THERAPEUTICS INC KYMR | $9.6m2.54% | Added +101.2k |
| MIRATI THERAPEUTICS INC MRTX | $8.1m2.14% | Reduced -161.7k |
| MERUS N V MRUS | $6.6m1.75% | New |
| VOR BIOPHARMA INC COM | $5.4m1.43% | Added +265.1k |
| ESPERION THERAPEUTICS INC NE ESPR | $5.4m1.42% | Added +318.0k |
| FULCRUM THERAPEUTICS INC FULC | $5.0m1.33% | New |
| ALPINE IMMUNE SCIENCES INC NVLS | $3.0m0.80% | New |
| GRACELL BIOTECHNOLOGIES INC SPONSORED ADS | $1.8m0.48% | Added +238.1k |
Sold out since Q4 2021
| Security | Value then |
|---|---|
| ARENA PHARMACEUTICALS INC ARNA | $23.4m251.8k shares |
| SEAGEN INC SGEN | $15.6m100.7k shares |
| ARGENX SE ARGX | $14.7m42.0k shares |
| INSMED INC INSM | $10.7m394.4k shares |
| GALAPAGOS NV LKFT | $9.3m167.8k shares |
| ENANTA PHARMACEUTICALS INC ENTA | $5.6m75.5k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 | 10.0%≈ $92.9m |
| EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 | 9.5%≈ $415.1m |
| ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 | 9.2%≈ $64.7m |
| ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 | 7.8%≈ $42.7m |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 6.1%≈ $123.5m |
| TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 | 5.8%≈ $110.9m |
| LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 | 5.3%≈ $19.4m |
| MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 | 5.2%≈ $137.6m |
| SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 | 5.1%≈ $395.7m |
| JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 | 5.1%≈ $69.0m |